Cancer

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations.

News

Cancer services should be rebuilt after COVID disruption, ex...

There is a pressing need for a joined-up cancer strategy to reverse the impact of the COVID-19 pandemic, according to a new report from the UK’s pharma industry.

News

COSMIC database matches drugs to cancer mutations

The world's largest database of cancer mutations can now be used to link mutations with drug treatments in what promises to be a step forward in precision oncology.

News

NICE axes funding for MSD's Keytruda in bladder cancer despi...

NICE has axed funding for MSD’s Keytruda for second-line advanced bladder cancer in final guidance, despite an appeal from the company.

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Rubius launches $200m IPO to fund red blood cell therapies

Rubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel cell therapies targeting cancer and autoimmune diseases.

News

Takeda buys Maverick as T-Cell engager research hots up

Takeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer therapies for $525 million, as research into the technology gathers pace.

Boehringer and MD Anderson extend KRAS cancer collaboration

Cancer services should be rebuilt after COVID disruption, ex...

COSMIC database matches drugs to cancer mutations

NICE axes funding for MSD's Keytruda in bladder cancer despi...

Rubius launches $200m IPO to fund red blood cell therapies

Takeda buys Maverick as T-Cell engager research hots up

AZ's gMG drug Klygefa nears EU approval

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks